Compare OFLX & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFLX | AVXL |
|---|---|---|
| Founded | 1975 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.4M | 397.6M |
| IPO Year | 2005 | N/A |
| Metric | OFLX | AVXL |
|---|---|---|
| Price | $27.85 | $4.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 33.6K | ★ 4.6M |
| Earning Date | 10-29-2025 | 11-25-2025 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $100,054,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.42 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.58 | $2.86 |
| 52 Week High | $48.58 | $14.44 |
| Indicator | OFLX | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 40.02 |
| Support Level | $26.84 | $3.62 |
| Resistance Level | $29.43 | $4.84 |
| Average True Range (ATR) | 1.00 | 0.42 |
| MACD | 0.28 | 0.23 |
| Stochastic Oscillator | 52.21 | 74.53 |
Omega Flex Inc is a manufacturer of flexible metal hoses, which is used in a variety of ways to carry gases and liquids within their particular applications. Omega sells its products under the TracPipe, CounterStrike, DoubleTrac, DEF-Trac and MediTrac brands. It serves various markets which include construction, manufacturing, transportation, petrochemical, pharmaceutical, and other industries. Geographically Omega Flex, Inc operates in the United States. The company derives revenues from the manufacture and sale of flexible metal hose and accessories.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.